Sponsored by The University of Chicago Booth School of Business and The University of Chicago Law School
Copyright 1987 The University of Chicago
Crossref reports the following articles citing this article:Peter T. Leeson, Henry A. Thompson Public choice and public health, 195, no.1-21-2 (Mar 2021): 5–41.Joseph T. F. Roberts How to Regulate the Right to Self-Medicate, 34, no.33 (Jun 2020): 233–255.Matthew J. Higgins, Xin Yan, Chirantan Chatterjee Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling, 50, no.11 (Jan 2021): 104126.Anqi Wu, Yixin (Iris) Wang The More Monitoring, the Better Quality? Empirical Evidence from the Generic Drug Industry, 23 (Jan 2019).David Barker Ethics and Lobbying: The Case of Real Estate Brokerage, 80, no.11 (Jun 2007): 23–35.Mary K. Olson The risk we bear: The effects of review speed and industry user fees on new drug safety, 27, no.22 (Mar 2008): 175–200.F.M. Scherer Uncertainty and choice: the challenges of pharmaceutical efficacy, safety, and cost, 28, no.4-54-5 (Aug 2007): 267–283.Ahmed Khwaja, Frank Sloan, Martin Salm Evidence on preferences and subjective beliefs of risk takers: The case of smokers, 24, no.44 (Jul 2006): 667–682.Gerald Keim Business and Public Policy, (Nov 2017): 585–603.Jean-Philippe Bonardi, Amy J Hillman, Gerald D. Keim The Attractiveness of Political Markets: Implications for Firm Strategy, 30, no.22 (Apr 2005): 397–413.Mary K. Olson Pharmaceutical Policy Change and the Safety of New Drugs Olson, 45, no.S2S2 (Jul 2015): 615–642.Theodore E. Keeler, Teh‐wei Hu, Alison Keith, Richard Manning, Martin D. Marciniak, Michael Ong, Hai‐Yen Sung The benefits of switching smoking cessation drugs to over‐the‐counter status, 11, no.55 (Jan 2002): 389–402.F.M. Scherer Chapter 25 The pharmaceutical industry, (Jan 2000): 1297–1336.Mark Thornton The Potency of Illegal Drugs, 28, no.33 (Jul 1998): 725–740.Anthony M. Marino Regulation of product safety design through product testing, 7, no.33 (May 1995): 255–276.W. Kip Viscusi Do Smokers Underestimate Risks?, 98, no.66 (Oct 2015): 1253–1269.Wesley A. Magat , and W. Kip Viscusi Effectiveness of the EPA's Regulatory Enforcement: The Case of Industrial Effluent Standards, 33, no.22 (Oct 2015): 331–360.